Clinical Guidelines

Beyond Morphology and IHC

Can molecular profiling and AI help uncover tumor origin and actionable biomarkers?

Share

  • 1

    Molecular testing improves diagnostics for cancers of unknown primary (CUP).

  • 2

    Traditional pathology methods often fail in ambiguous cases.

  • 3

    AI tools are becoming integral in diagnostic workflows.

  • 4

    Molecular findings guide treatment decisions for targeted therapies.

  • 5

    Next-generation sequencing distinguishes between separate primaries and metastases.

  • 6

    Multidisciplinary discussions are essential for testing decisions.

  • 7

    Uncovering biomarkers can lead to broader treatment options.

Original Source(s)

Beyond Morphology and IHC

  • by Jessica Allerton

  • March 16, 2026

Related Content

Vitamin D Deficiency and Bone Disease

Review finds limited evidence that common vitamin D deficiency cutoffs consistently reflect bone disease risk in community dwellers

Value-based Healthcare: The Vision

Founding members of the Santa Fe Project discuss the role of pathology in improving population-level health

Can Apps Improve Urgent Care Diagnoses?

Researchers assess a digital symptom history app in urgent care, comparing physician diagnoses with expert review and follow-up care.